This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / FDA Accepts Hansa Biopharma's Imlifidase BLA
Regulatory drug approval

FDA Accepts Hansa Biopharma's Imlifidase BLA

Analysis based on 7 articles · First reported Mar 04, 2026 · Last updated Mar 13, 2026

Sentiment
40
Attention
2
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The acceptance of the imlifidase BLA by the United States===Food and Drug Administration is a positive development for Hansa Biopharma, potentially leading to increased investor confidence and stock performance. It also signals a potential new treatment option for kidney transplant patients, impacting the broader healthcare market.

Biotechnology Pharmaceuticals
Event Summary

The United States===Food and Drug Administration has accepted the Biologics License Application (BLA) for imlifidase, a drug developed by Hansa Biopharma, for review. Imlifidase is intended for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. The BLA is supported by data from the phase 3 ConfldeS trial, which demonstrated superior kidney function and dialysis independence for patients treated with imlifidase compared to control. A Prescription Drug User Fee Act target date of December 19, 2026, has been set for the application. Renée Aguiar-Lucander, CEO of Hansa Biopharma, highlighted this as a significant milestone for the company and patients awaiting kidney transplantation.

Key Actions
90 Hansa Biopharma developed and submitted Biologics License Application for imlifidase United States===Food and Drug Administration
Entities Involved
stock
Hansa Biopharma
Hansa Biopharma is the developer of imlifidase, and the acceptance of its Biologics License Application by the United States===Food and Drug Administration marks an important milestone for the company. This development brings Hansa Biopharma closer to potentially offering a transformative therapy option for kidney transplant patients.
Importance 95 Sentiment 60
govactor
United States===Food and Drug Administration
The United States===Food and Drug Administration has accepted the Biologics License Application for imlifidase for review, setting a Prescription Drug User Fee Act target date of December 19, 2026. This action moves imlifidase closer to potential market approval in the United States.
Importance 80 Sentiment 20
per
Renée Aguiar-Lucander
Renée Aguiar-Lucander, CEO of Hansa Biopharma, expressed optimism about the United States===Food and Drug Administration's acceptance of the imlifidase BLA, highlighting its importance for the company and patients.
Importance 40 Sentiment 50
Relationships
Renée Aguiar-Lucander related ↔ Hansa Biopharma
United States===Food and Drug Administration related ↔ Hansa Biopharma
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.